Smallpox vaccine alternative identified

University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.

Philip Felgner and Huw Davies with the Department of Medicine found that the modified vaccinia virus Ankara (MVA) produced the same antiviral response in human and animal studies as the current smallpox vaccine, Dryvax. The study is part of a national effort to develop a replacement for the Dryvax vaccine, which causes serious complications in some people. The results are published in the Journal of Virology.

“Studies have shown MVA to be a much safer vaccine product that takes advantage of modern technology,” Felgner said. “We are pleased that our advanced analytical methods may help to bring an effective and safer vaccine to the public.”

Smallpox was declared eradicated worldwide in 1980; the last naturally occurring case in the world was in Somalia in 1977. Routine vaccination against smallpox in the U.S. stopped in 1972, and Dryvax production was halted in 1982.

Both Dryvax and MVA are strains of vaccinia virus, which is related to the smallpox virus. The antibodies created by vaccinia virus infection protect a person against a lethal smallpox infection, making it suitable for use as a vaccine. Unlike smallpox virus, vaccinia creates a very mild infection and is completely safe for healthy individuals.

Although Dryvax was effective during the eradication campaign in the 1960s and ’70s, its manufacturing methods are outdated by today’s standards, and it is also associated with significant risk of adverse reactions for immune-compromised individuals.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, identified MVA as a possible candidate to replace Dryvax. MVA was first developed in the 1970s and has been administered to animal species and humans with little or no adverse side effects.

In the study, Felgner and Davies applied blood serum samples taken from both humans and animals given the MVA or Dryvax vaccines to “microarray” chips containing more than 200 vaccinia virus proteins, on which they simultaneously studied how the serum antibodies responded to all the vaccinia proteins.

The researchers found that these antibody responses were similar in both the animal and human subjects regardless whether they were given MVA or Dryvax, suggesting that MVA contains antiviral properties similar to those in Dryvax.

This similarity is vital, Davies says, because if a vaccine initiates an immune response in humans that matches the one in animals that are protected against lethal pox viruses, then public health officials will have more confidence that the vaccine will be effective in humans.

“This is particularly important for vaccines against lethal infections like smallpox, where human clinical trials cannot be done,” he added.

Source: University of California - Irvine

Related stories:

Fever after smallpox vaccination tied to individual genetic variations
St. Louis researchers have identified common DNA variations that underlie susceptibility to fever after smallpox vaccination. Their finding is the first to link individual differences written into the genetic code with a vaccine-related complication – albeit a mild one.
Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?
In the event of a smallpox outbreak in the United States, how long would it take for a vaccinSLU scientist leads national studye to start protecting Americans by stimulating an immune response?
Potatoes may hold key to Alzheimer's treatment
A virus that commonly infects potatoes bears a striking resemblance to one of the key proteins implicated in Alzheimer's disease (AD), and researchers have used that to develop antibodies that may slow or prevent the onset of AD.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.
Effective health messages may yield vaccine compliance among ER workers
Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying. In order to protect themselves and allow them to care for the public, these first responders need to be fully prepared by getting available vaccines now.
Researchers discover new cellular mechanism that will significantly advance vaccine development
La Jolla Institute for Allergy & Immunology (LIAI) scientists have discovered one for the textbooks. Their finding, reported Friday in the scientific journal Immunity, illuminates a new, previously unknown mechanism in how the body fights a virus. The finding runs counter to traditional scientific understanding of this process and will provide scientists a more effective method for developing vaccines.
The most natural drug
In the fight against infection, the human immune system isn’t ready for a war. Vaccines push the immune system to create defenses against illness, but they take time to work. A new process developed by scientists at the Oklahoma Medical Research Foundation (OMRF) and Emory University stands to revolutionize the process.
Nanoemulsion vaccines show increasing promise
A novel technique for vaccinating against a variety of infectious diseases – using an oil-based emulsion placed in the nose, rather than needles – has proved able to produce a strong immune response against smallpox and HIV in two new studies.

News discussion:

Medicine & Health news